Median (IQR) of overall population risk per algorithm by site and by sex, AWI-Gen baseline data
| Median (IQR) | Framingham (office) | Framingham (lab) | Globorisk (office) | Globorisk (lab) | WHO-CVD (office) | WHO-CVD (lab) |
| Nanoro | ||||||
| Men | 8.1% (5.5–11.4) | 5.8% (3.8–8.4) | 5.1% (3.2–7.7) | 4.7% (2.7–7.1) | 2.6% (1.7–3.9) | 2.6% (1.6–3.8) |
| Women | 2.6% (1.8–4.1) | 1.9% (1.3–2.9) | 2.8% (1.9–4.1) | 2.2% (1.4–3.4) | 1.7% (1.1–2.6) | 1.6% (1.0–2.4) |
| All | 4.8% (2.6–8.5) | 3.4% (1.9–6.2) | 3.6% (2.3–6.0) | 3.1% (1.9–5.4) | 2.1% (1.3–3.3) | 2.0% (1.2–3.1) |
| Navrongo | ||||||
| Men | 10.6% (7.0–15.0) | 6.5% (4.3–10.3) | 7.3% (4.9–10.6) | 6.6% (4.2–9.8) | 3.5% (2.2–5.1) | 3.1% (2.0–4.7) |
| Women | 4.0% (2.7–6.1) | 2.7% (1.8–4.4) | 5.3% (3.6–8.0) | 4.3% (2.8–7.0) | 2.5% (1.6–3.6) | 2.2% (1.4–3.3) |
| All | 6.3% (3.7–11.3) | 4.2% (2.4–7.3) | 6.2% (4.1–9.3) | 5.3% (3.4–8.3) | 2.9% (1.9–4.3) | 2.6% (1.7–3.9) |
| Dikgale | ||||||
| Men | 12.8% (7.9–20.6) | 9.3% (5.7–15.8) | 8.7 (4.6–14.5) | 7.8% (4.1–13.9) | 4.1% (2.6–6.4) | 3.9% (2.4–5.9) |
| Women | 5.6% (3.2–9.4) | 4.3% (2.5–7.0) | 4.4% (2.3–7.4) | 3.3% (1.7–5.6) | 3.1% (1.9–4.6) | 2.8% (1.7–4.2) |
| All | 7.3% (4.0–12.3) | 5.4% (3.0–9.3) | 5.2% (2.8–9.3) | 4.1% (2.1–7.4) | 3.3% (2.1–5.1) | 3.0% (1.8–4.7) |
| Agincourt | ||||||
| Men | 12.4% (7.7–17.9) | 8.6% (5.3–13.1) | 9.3% (5.1–14.6) | 8.0% (4.0–12.8) | 4.2% (2.7–6.1) | 3.7% (2.3–5.4) |
| Women | 6.4% (3.7–10.4) | 4.7% (2.7–8.0) | 5.0% (2.5–8.2) | 3.7% (1.9–6.2) | 3.4% (2.1–5.0) | 3.1% (1.9–4.6) |
| All | 8.3% (4.8–13.8) | 6.1% (3.5–10.1) | 6.4% (3.2–10.4) | 4.9% (2.4–8.6) | 3.8% (2.3–5.4) | 3.3% (2.0–4.8) |
| Nairobi | ||||||
| Men | 8.2% (5.6–12.4) | 6.3% (4.2–9.9) | 3.6% (2.4–5.4) | 3.4% (2.2–5.2) | 3.0% (2.0–4.7) | 2.9% (1.9–4.5) |
| Women | 3.4% (2.2–5.7) | 2.9% (1.7–4.8) | 1.5% (0.6–2.4) | 1.3% (0.8–2.2) | 1.9% (1.3–2.9) | 1.8% (1.2–2.8) |
| All | 5.4% (3.1–9.4) | 4.3% (2.5–7.4) | 2.3% (1.3–3.9) | 2.1% (1.1–3.7) | 2.4% (1.5–3.7) | 2.2% (1.4–3.6) |
| Soweto | ||||||
| Men | 13.1% (8.4–19.7) | 9.8% (6.0–14.8) | 9.4% (5.1–15.6) | 8.1% (4.4–13.7) | 4.5% (2.8–6.9) | 3.9% (2.5–5.9) |
| Women | 5.7% (3.8–8.9) | 6.0% (3.5–9.9) | 4.7% (2.6–7.9) | 3.3% (1.7–5.6) | 3.1% (2.0–4.8) | 2.7% (1.7–4.1) |
| All | 8.9% (5.3–15.3) | 7.9% (4.7–12.8) | 6.6% (3.5–11.8) | 5.2% (2.7–10.3) | 3.8% (2.4–5.8) | 3.3% (2.01–5.1) |
| Total | ||||||
| Men | 10.1% (6.6–15.5) | 7.1% (4.6–11.4) | 6.2% (3.6–10.6) | 5.7% (3.2–9.7) | 3.5% (2.2–5.3) | 3.2% (2.0–4.9) |
| Women | 4.2% (2.6–7.3) | 3.3% (1.9–6.0) | 3.6% (1.9–6.3) | 2.8% (5.0–1.5) | 2.5% (1.6–3.9) | 2.2% (1.4–3.5) |
| All | 6.5% (3.7–11.4) | 4.9% (2.7–8.7) | 4.6% (2.5–8.2) | 3.8% (2.0–7.1) | 2.9% (1.8–4.5) | 2.6% (1.6–4.1) |
| population 10-year CVD risk | <3% | 3%–6% | >6%–9% | >9%–13% | >13% | |
AWI-Gen, Africa-Wits-INDEPTH partnership for Genomic studies; CVD, cardiovascular disease.